Interferon Apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 4, 2014, Pages 1681-1684

  Zhang, Zhi Rong ^a   Duan, Yan Chao ^a  

^a TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

Alpha 2 b; Essential thrombocytosis; Interferon; JAK2V617F mutation; Polycythemia vera

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; HYDROXYUREA; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; THROMBOCYTHEMIA; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; RECOMBINANT PROTEINS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS; TREATMENT OUTCOME;

EID: 84896907518     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.4.1681     Document Type: Article

References (16)

1. Bai J, Xue YP, Zhang L, et al (2011). Interferon-alpha-2b Induces Molecular Responses of Patients with Polycythemia Vera and Its Post-polycythemic Myelofibrosis. J Exp Haematol, 19, 444-9.
2. Barbui T, Finazzi MC, Finazzi G, et al (2012). Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev, 26, 205-11.
3. Barosi G, Birgegard G, Finazzi G, et al (2009). Response criteria for essential thrombocythemia and poly-cythemia vera: result of a European Leukemia Net consensus conference. Blood, 113, 4829-33.
4. Chawla-Sarkar M, Lindner DJ, Liu YF, et al (2003). Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis, 8, 237-49.
5. Dai CH, Price JO, Brunner T, et al (1998). Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood, 91, 1235-42.
6. Dirican A, Kucukzeybek Y, Erten C, et al (2013). Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 14, 2101-5.
7. Eickelberg O, Pansky A, Koehler E, et al (2001). Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J, 15, 797-806.
8. Guo Y, Wang G, Gao WW, et al (2012). Induction of apoptosis in glioma cells and upregulation of Fas expression using the human interferon gene. Asian Pac J Cancer Prev, 13, 2837-40.
9. Hasselbalch HC (2011). A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol, 4, 637-55.
10. Kiladjian JJ, Cassinat B, Chevret S, et al (2008). Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood, 112, 3065-72.
11. Laljee RP, Muddaiah S, Salagundi B, et al (2013). Interferon stimulated gene-ISG15 is a potential diagnostic biomarker in oral squamous cell carcinomas. Asian Pac J Cancer Prev, 14, 1147-50.
12. Larsen TS, Pallisgaard N, Moller MB, et al (2007). The JAK2 V617F alleleburden in essential thrombocythemia, polycythemia vera and primary myelofi-brosis-impact on disease phenotype. Eur J Haematol, 79, 508-15.
13. Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al (2013). Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood, 122, 893-901.
14. Rizza P, Moretti F, Belardelli F et al (2010). Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity. 43, 204-9
15. Wang Q, Miyakawa Y, Fox N, et al (2000). Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood, 96, 2093-9.
16. Zhao YH, Wang T, Yu GF, et al (2013). Anti-proliferation effects of interferon on gastric cancer cells. Asian Pac J Cancer Prev, 14, 5513-8.